HilleVax gains after starting norovirus vaccine trial

HilleVax

02/05/2022 19:13

** Shares of vaccine developer  HLVX.O  rise nearly 4% to
$19.84 on their second day of trading after late-April IPO
    ** HLVX says it has dosed the first subjects in a mid-stage
clinical trial testing HIL-214, its vaccine candidate for the
prevention of moderate-to-severe acute gastroenteritis caused by
norovirus infection  urn:newsml:reuters.com:*:nGNX57jPn5
    ** Norovirus is a very contagious virus which can lead to 
inflammation of the stomach or intestines (gastroenteritis) with
symptoms including diarrhea and vomiting
    ** Each year, there are about 2,500 reported norovirus
outbreaks in the United States, according to the Centers for
Disease Control and Prevention 
    ** Including session's gains, stock up 16.7% from IPO price
of $17 per share 

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))